Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ACVR2B antisense RNA 1 (ACVR2B-AS1)
- Target
- ACVR2B-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Other (Non-protein coding RNA)
01
Overview
ACVR2B-AS1 is a long non-coding RNA transcribed antisense to the activin receptor type IIB (ACVR2B) gene on chromosome 3p22.2[1][6]. It is involved in regulatory functions, potentially modulating expression of neighboring protein-coding genes such as ACVR2B. ACVR2B-AS1 expression is upregulated in several cancers, including liver cancer, where it is associated with poor prognosis and may act as a biomarker for adverse clinical outcomes[1][3]. Recent studies indicate that ACVR2B-AS1 plays a role in stem cell maintenance and apoptosis by interacting with glycolytic enzyme ALDOA, thereby influencing glycolysis and cell fate in human spermatogonial stem cells[5]. Its full mechanistic roles are not yet experimentally dissected, and no direct therapeutic drugs target it. However, its inclusion in immuno-oncology panels and links to pathways such as PI3K-Akt suggest a possible role in modulating tumor microenvironment and cancer progression[3].
- Other names
- ACVR2B-AS1ACVR2B antisense RNA 1 (non-protein coding)Activin A receptor type 2B antisense RNA 1
02
Biological functions
Regulation of self-renewal and apoptosis in human spermatogonial stem cells (SSCs) through interaction with ALDOA via modulation of glycolysisPotential local regulation of neighboring gene ACVR2B (encoding activin receptor type IIB) via transcriptional interference or chromatin structure modificationPossible involvement in immune-related gene expression and tumor microenvironment signaling (e.g., PI3K-Akt and focal adhesion pathways)Cell proliferation and cell death (as inferred from regulation of SSC fate)
03
Disease associations
Prognostic biomarker and potential therapeutic target in liver cancerPrognostic biomarker in thyroid cancer (especially papillary thyroid cancer)Possible association with endometrial and breast cancer (prognostic signatures studied)Potential relevance in male infertility via regulation of SSCs
04
Biomarkers
ACVR2B-AS1 expression is an independent biomarker for prognosis and risk stratification in liver cancerACVR2B-AS1 expression is an independent biomarker for prognosis and risk stratification in thyroid cancer
Beyond the preview
Go deeper on ACVR2B antisense RNA 1 (ACVR2B-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACVR2B antisense RNA 1 (ACVR2B-AS1).